Market Overview

Vir Biotech 'Aggressively Working' On Potential Wuhan Coronavirus Treatment

Share:
Vir Biotech 'Aggressively Working' On Potential Wuhan Coronavirus Treatment

Shares of Vir Biotechnology Inc (NASDAQ: VIR), which went public in October, are poised to trade sharply higher after the San Francisco-based company announced a multi-pronged strategy for tacking the deadly coronavirus that originated in the Wuhan province of China and has spread panic wave across the globe on a possible contagion.

Vir late Wednesday said it's working rapidly to determine whether its previously identified anti-coronavirus monoclonal antibodies, or mAbs, possess the potential to bind and neutralize the Wuhan coronavirus, aka 2019-nCoV.

These mAbs, according to the company, were discovered using its antibody platform from the survivors of an infection. Some of these may have the potential to treat and prevent Wuhan coronavirus.

See Also: Co-Diagnostics Rallies On Plans To Develop Screening Test For Coronavirus

Vir said it's exploring the isolation of new mAbs specific to the virus.

Additionally, the company said its scientists are planning to apply whole genome CRISP-based screening capabilities to identify the host receptor that allows Wuhan coronavirus infection.

"We appreciate the threat this pathogen presents, and are utilizing our technologies to determine whether we currently have, or can identify, therapies to neutralize this virus," said George Scangos, CEO of Vir.

Vir shares were advancing 15.11% to $19.04 at time of publication.

Posted-In: coronavirus Wuhan coronavirusBiotech News Movers Trading Ideas General Best of Benzinga

 

Related Articles (VIR)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com